Literature DB >> 2695841

In vitro antifungal activity of saperconazole (R 66905) against Candida and Torulopsis.

M Mallié, B Montès, J C Lebecq, J M Bastide.   

Abstract

The susceptibility of several strains of Candida and Torulopsis to saperconazole, a new triazole antifungal compound, was compared to that of ketoconazole. The MICs of the two antifungal agents were determined against 70 strains of Candida albicans, 10 strains of C. guilliermondii, 10 strains of C. krusei, 10 strains of C. parapsilosis, 10 strains of C. pseudotropicalis, 10 strains of C. tropicalis and 15 strains of Torulopsis glabrata. The fungistatic activity was evaluated by the agar dilution method using BHI and casitone media after incubation for 48 hours at 28-30 degrees C. The in vitro activity of saperconazole was similar to that of ketoconazole for most of the Candida spp. tested except for C. krusei in particular. An MIC of less than or equal to 3.12 micrograms/ml for saperconazole was found with 92% of the C. albicans strains tested. In contrast, T. glabrata was more susceptible to ketoconazole.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2695841     DOI: 10.1111/j.1439-0507.1989.tb02195.x

Source DB:  PubMed          Journal:  Mycoses        ISSN: 0933-7407            Impact factor:   4.377


  2 in total

1.  Susceptibility of clinical isolates of fungi to saperconazole.

Authors:  M Otcenásek
Journal:  Mycopathologia       Date:  1992-06       Impact factor: 2.574

2.  Saperconazole therapy of murine disseminated candidiasis: efficacy and interactions with amphotericin B.

Authors:  A M Sugar; M Salibian; L Z Goldani
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.